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Introduction
Colorectal cancer (CRC) is one of the most common 
cancers in both men and women, and remains one of 
the leading causes of cancer- related death worldwide [1]. 
Declining incidence rates and improvements in early detec-
tion and treatment have led to reduced overall mortality 
rates, but outcomes in patients with metastatic disease 
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Abstract
Circulating protein markers were assessed in patients with colorectal cancer 
(CRC) treated with cetuximab in CALGB 80203 to identify prognostic and 
predictive biomarkers. Patients with locally advanced or metastatic CRC received 
FOLFOX or FOLFIRI chemotherapy (chemo) or chemo in combination with 
cetuximab. Baseline plasma samples from 152 patients were analyzed for six 
candidate markers [epidermal growth factor (EGF), heparin- binding EGF (HBE-
GF), epidermal growth factor receptor (EGFR), HER2, HER3, and CD73]. Analyte 
levels were associated with survival endpoints using univariate Cox proportional 
hazards models. Predictive markers were identified using a treatment- by- marker 
interaction term in the Cox model. Plasma levels of EGF, HBEGF, HER3, and 
CD73 were prognostic for overall survival (OS) across all patients (KRAS mutant 
and wild- type). High levels of EGF predicted for lack of OS benefit from ce-
tuximab in KRAS wild- type (WT) patients (chemo HR = 0.98, 95% CI = 0.74–
1.29; chemo+cetuximab HR = 1.54, 95% CI = 1.05–2.25; interaction P = 0.045) 
and benefit from cetuximab in KRAS mutant patients (chemo HR = 1.72, 95% 
CI = 1.02–2.92; chemo+cetuximab HR = 0.90, 95% CI = 0.67–1.21; interaction 
P = 0.026). Across all patients, higher HER3 levels were associated with signifi-
cant OS benefit from cetuximab treatment (chemo HR = 4.82, 95% CI = 1.68–
13.84; chemo+cetuximab HR = 0.95, 95% CI = 0.31–2.95; interaction P = 0.046). 
CD73 was also identified as predictive of OS benefit in KRAS WT patients 
(chemo HR = 1.28, 95% CI = 0.88–1.84; chemo+cetuximab HR = 0.60, 95% 
CI = 0.32–1.13; interaction P = 0.049). Although these results are preliminary, 
and confirmatory studies are necessary before clinical application, the data sug-
gest that HER3 and CD73 may play important roles in the biological response 
to cetuximab.
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remain poor with an estimated 5- year relative survival 
rate of approximately 12% [1, 2]. Therapies targeting the 
activation and signaling of epidermal growth factor recep-
tor (EGFR/HER1/ERBB1) have improved outcomes, but 
essentially all patients will develop treatment resistance 
and progress [3, 4]. Improving outcomes in these patients 
is predicated on refining our understanding of the rela-
tionship between receptor expression and downstream 
signaling pathways.
EGFR is a member of the HER/ERBB family of recep-
tor tyrosine kinases (RTKs) that also includes HER2/
ERBB2, HER3/ERBB3, and HER4/ERBB4. Ligand binding 
to the extracellular domains of these receptors results 
in their homo- and hetero- dimerization, leading to acti-
vation of their intracellular kinase domains [5]. HER- 
family RTKs are activated by several ligands, including 
epidermal growth factor (EGF) and heparin- binding EGF 
(HBEGF), leading to differential activation of multiple 
downstream signaling pathways [6]. Hetero- dimerization 
between members of this RTK family provides specificity 
to the downstream signaling initiated by the ligands that 
bind these receptors, but also provides potential avenues 
for resistance to cetuximab, as well as other agents, that 
target the activity of a single member of this receptor 
family [7, 8].
Cetuximab is a monoclonal antibody that binds EGFR 
and competitively inhibits its interaction with EGF [9]. 
Cetuximab is associated with improved clinical outcomes 
in metastatic CRC (mCRC) and advanced head and neck 
cancer [10, 11]. The Cancer and Leukemia Group B 
(CALGB, now The Alliance for Clinical Trials in Oncology) 
80203 trial was initiated to evaluate the efficacy of cetuxi-
mab as first- line treatment of mCRC in combination with 
FOLFOX or FOLFIRI chemotherapy, but it was closed 
upon the approval of bevacizumab as first- line treatment 
for mCRC in 2004 and its analysis plan was redesigned 
as a randomized phase II trial. CALGB 80405 was sub-
sequently initiated as a head- to- head comparison of beva-
cizumab versus cetuximab in combination with FOLFOX 
or FOLFIRI chemotherapy. The clinical data of both trials 
have been previously reported [12, 13].
The search for predictive biomarkers for EGFR- targeting 
therapies has included analyses of amplifications of the 
EGFR gene [14], amplifications of the hepatocyte growth 
factor receptor (cMET) [15], genome- wide DNA methyla-
tion status [16], and both candidate- based and unbiased 
surveys of gene transcription [17–19]. Currently, activating 
mutations in the RAS genes (codons 12, 13, 61, 117, 
and 146 of KRAS and NRAS) or BRAF codon 600 (exon 
15) are the only validated biomarkers of resistance to 
cetuximab and other EGFR- targeting therapies in mCRC 
in widespread clinical use [20–23]. It is important to 
note that CALGB 80203 was initiated before the routine 
incorporation of KRAS mutational testing. These patients 
were retrospectively screened for mutations in codons 
12 and 13, but they have not been analyzed using the 
more comprehensive RAS mutation screening that is now 
considered standard of care [24]. Because patients with 
KRAS mutant (Mut) tumors are no longer treated with 
cetuximab this study provides access to a distinctive patient 
population. Recognizing the need to develop additional 
biomarkers that may predict for sensitivity and resistance 
to cetuximab, as well as prognostic markers that could 
guide the management of patients with mCRC, plasma 
and serum were collected at baseline during CALGB 
80203.
Previously, we identified several prognostic and predic-
tive biomarkers of benefit from cetuximab in patients 
enrolled in CALGB 80203 using mRNA isolated from 
formalin- fixed paraffin- embedded (FFPE) tumor tissue 
[17]. That analysis indicated that HER3 and NT5E (CD73) 
mRNA expression were predictive of benefit from cetuxi-
mab. In this report, we have continued our analysis of 
CALGB 80203 and assessed the levels of EGFR- related 
proteins in plasma. Plasma levels of EGF, HBEGF, soluble 
EGFR, soluble HER2/ERBB2, soluble HER3/ERBB3, and 
soluble CD73 were quantified using multiplex ELISA- based 
methods. Blood- based biomarkers hold several advantages 
over fresh tumor biopsies, including reduced risks and 
costs, broader availability, and the ability to be monitored 
throughout the course of treatment. This is one of the 
first reports to identify prognostic and predictive blood- 
based biomarkers from a randomized trial using cetuximab 
in the first- line treatment of mCRC.
Materials­and­Methods
Sample­collection
Peripheral venous blood was collected at baseline from 
consenting patients into vacutainers containing EDTA 
anticoagulant. Samples were centrifuged at 2500g for 
15 min within 30 min of collection. Plasma was aliquoted, 
frozen in liquid nitrogen, and shipped to the CALGB 
(now part of the Alliance for Clinical Trials in Oncology) 
Pathology Coordinating Office for centralized storage. For 
these analyses, samples were shipped to our laboratory 
(Duke/Alliance Molecular Reference Lab) thawed on ice, 
realiquoted, and stored at −80°C prior to use.
Study­design­and­patients
Design details of the CALGB 80203 study have been pre-
viously described [12]. Patients with previously untreated, 
advanced, or metastatic adenocarcinoma of the colon or 
rectum were assigned to FOLFIRI, FOLFIRI plus 
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cetuximab, FOLFOX, or FOLFOX plus cetuximab treat-
ment groups. This was a multicenter trial approved by 
the institutional review boards at each participating insti-
tution, and all the patients included in the analyses reported 
here provided consent. Of the patients who consented 
but were found to be ineligible, one patient did not have 
colorectal cancer and the other patient had no evaluable 
disease. This retrospective analysis conforms to the report-
ing guidelines established by the REMARK criteria.
Plasma­protein­analysis
EGF, HBEGF, EGFR, and HER2 were analyzed using the 
Searchlight platform (Aushon Biosystems, Inc., Billerica, 
MA) following the manufacturer’s protocol. Plasma sam-
ples were thawed on ice, centrifuged at 20,000g for 5 min, 
loaded onto SearchLight plates with standards, and incu-
bated at room temperature for 1 h while shaking at 
950 rpm (Lab- Line Titer Plate Shaker, Model 4625, 
Barnstead, Dubuque, WI). All washing steps were per-
formed using a plate washer (model ELx405; Biotek 
Instruments, Inc., Winooski, VT). After washing, bioti-
nylated secondary antibody was added, and plates were 
incubated for 30 min, washed, streptavidin- HRP was 
added, incubated for 30 min, and plates were washed 
again. SuperSignal substrate reagent was added after the 
final wash, images were collected within 10 min, and 
images were analyzed using SearchLight array analyst 
software.
HER3 and CD73 were analyzed using assays developed 
in our laboratory using the Meso Scale Discovery ELISA 
platform (Meso Scale Discovery, Rockville, MD). For HER3, 
ELISA plates were coated overnight with 4 μg/mL HER3 
capture antibody (MAB3481; R&D Systems, Minneapolis, 
MN). After sample incubation, HER3 was detected using 
1 μg/mL biotinylated HER3 antibody (MN BAF234; R&D 
Systems) and 5 μg/mL streptavidin- conjugated SulfoTag 
(R32AD- 5; Meso Scale Discovery). For CD73, ELISA plates 
were coated overnight with 3.3 μg/mL CD73 capture anti-
body (550256; BD Biosciences, San Jose, CA). After sample 
incubation, CD73 was detected using 1 μg/mL antibody 
(41- 0200; Invitrogen/Life Technologies, Grand Island, NY) 
conjugated to MSD Sulfo- Tag according to the manufac-
turer’s instructions (R91AN- 1, Meso Scale Discovery). 
Samples were quantified using MSD Discovery Workbench 
software version 3.0.18 (Meso Scale Discovery). All assays 
were performed in duplicate and laboratory personnel 
were blinded to clinical outcome.
KRAS­mutational­analysis
KRAS mutation analysis was performed in the CALGB/
Alliance molecular reference laboratory of Dr. Greg 
Tsongalis at Dartmouth Medical School using the 
TheraScreen KRAS Mutation Test Kit (870021; Qiagen, 
Manchester, UK).
RNA­Isolation
The isolation and quantification of mRNA transcripts using 
real- time PCR was previously reported [17].
Statistical­analysis
Prognostic analyses were performed using baseline data 
from all available patients independent of treatment arm, 
with continuous values for the protein analytes. All marker 
levels were log- transformed before analysis. Markers prog-
nostic of clinical outcome (overall survival [OS] or 
progression- free survival [PFS]) were determined using 
univariate Cox [29] proportional hazards models, and the 
resulting hazard ratios (HR), 95% confidence intervals 
(CI), and P- values are reported. For each clinical outcome 
(OS or PFS) multivariate Cox regression models were 
used to test for interaction between marker level and 
treatment (chemo vs. chemo+cetuximab), to identify mark-
ers predictive of benefit from cetuximab. To further assess 
the role that KRAS mutational status has on subsequent 
biomarker determinations, the analyses were repeated for 
patients with KRAS wild- type (WT) only and for KRAS 
Mut tumors only. Kendall’s tau coefficient [26] was used 
to test for correlation between plasma protein levels and 
tumor mRNA expression for each marker using the subset 
of the analysis population for which both samples were 
available. P- values were not adjusted for multiple 
testing.
Forest plots were created to depict the prognostic effect 
sizes (HRs and corresponding 95% CIs) of the different 
marker levels. For selected predictive markers, marker level 
was dichotomized at the median as “high” or “low”, and 
Kaplan–Meier [27] plots of OS or PFS were created with 
separate curves for each combination of treatment group 
and marker level.
The Alliance Statistics and Data Center conducted data 
collection and statistical analyses, and the clinical data 
were locked as of March 5, 2012. The R software envi-
ronment for statistical computing and graphics [28] and 
the survival [25] package were used to execute the sta-
tistical analyses and to generate the figures.
Results
Patient­characteristics
The characteristics of the overall patient population were 
reported previously [12]. Plasma samples were available 
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for biomarker analysis from 152 of the 238 patients 
enrolled. The characteristics of this biomarker population 
reflected the characteristics of the overall study population 
(Table 1). As previously reported, there were no observed 
differences in outcomes between the groups that received 
FOLFOX or FOLFIRI chemotherapy, so these groups were 
combined into chemotherapy (chemo) alone (FOLFOX 
or FOLFIRI) and chemo+cetuximab groups for this analy-
sis. No significant differences in the characteristics of the 
chemo and chemo+cetuximab groups were observed. KRAS 
mutational analysis was limited to the seven common 
mutations of the KRAS gene at codons 12 and 13. Extended 
RAS mutational analyses were not performed. KRAS muta-
tional status was only available for 116 (76.3%) of the 
patients in this group. In the blood- based biomarker 
cohort the rate of KRAS mutation is 39.7%, slightly less 
than the rate of 43.0% in the parent study and 46.6% 
in our previous analysis of mRNA expression from FFPE 
samples [12, 17]. A CONSORT diagram is presented in 
Figure 1.
Biomarker­characteristics
The six markers of interest were chosen based on their 
direct role in EGFR signaling, previous examination of 
mRNA levels in archived FFPE tumor samples, and the 
availability of high- quality assays to accurately assess 
each soluble marker in patient plasma. The levels of 
EGFR markers in blood were measured and tested for 
association with both OS and PFS outcomes. The 
characteristics of the assayed markers are shown in Table 
S1. The EGFR ligands (EGF, HBEGF) were present at 
lower levels compared to the soluble receptors, and were 
observed to have higher levels of variability between 
patients. Baseline levels of the EGF and HBEGF ligands 
were positively correlated (Kendall rank correlation coef-
ficient τ = 0.34), as were levels of HER2 and HER3 
(τ = 0.33). No other marker pairs showed strong cor-
relations (Table S2). Additionally, there was no associa-
tion observed for any marker tested and KRAS mutation 
status (data not shown).
Prognostic­marker­analyses
The prognostic association of protein levels with survival 
endpoints (PFS and OS) was examined in the overall 
population (Fig 2, panels A and B) as well as in the 
KRAS WT (Fig. 2, panels C and D) and KRAS Mut (Fig. 2, 
panels E and F) groups separately.
In the overall population, higher EGF protein levels 
were prognostic for shorter PFS (HR = 1.16, 95% 
CI = 1.01–1.34, P = 0.034) and OS (HR = 1.25, 95% 
CI = 1.09–1.45, P = 0.002) (Fig. 2, panels A and B). 
In the KRAS WT group, no association was observed 
between EGF and PFS (P = 0.482), but EGF levels 
showed a trend toward being prognostic for OS 
(HR = 1.21, 95% CI = 0.99–1.49, P = 0.068). In the 
KRAS Mut group, no prognostic associations were 
observed between EGF and PFS (P = 0.913) or OS 
(P = 0.596).
In the overall population, no prognostic association 
between HBEGF and PFS was observed (P = 0.13). For 
OS, higher HBEGF levels were prognostic in all patients 
for shorter OS (HR = 1.49, 95% CI = 1.03–2.16, P = 0.035). 
No prognostic association between HBEGF and PFS was 
observed in the KRAS WT group (P = 0.74). Higher 
HBEGF levels showed a trend toward being prognostic 
for shorter OS in KRAS WT patients (HR = 1.61, 95% 
Table 1. Patient characteristics.
Chemo 
(N = 76)
Chemo+cetuximab 
(N = 76)
Total 
(N = 152)
P-value
Age Number 
(%Total)
Number  
(%Total)
Number 
(%Total)
0.24
20–29    2 (2.6)    1 (1.3)    3 (2.0)
30–39    5 (6.6)    3 (3.9)    8 (5.3)
40–49    7 (9.2) 13 (17.1) 20 (13.2)
50–59 20 (26.3) 15 (19.7) 35 (23.0)
60–69 29 (38.2) 22 (28.9) 51 (33.6)
70+ 13 (17.1) 22 (28.9) 35 (23.0)
Gender 0.87
Male 47 (61.8) 49 (64.1) 96 (64.5)
Female 29 (38.2) 27 (35.9) 56 (35.5)
Race 0.33
White 64 (84.2) 69 (90.8) 133 (87.5)
ECOG PS 0.19
0 34 (44.7) 43 (56.6) 77 (50.7)
1 42 (55.3) 33 (43.4) 75 (49.3)
KRAS status 1.00
Missing 20 16 36
KRAS Mut 22 (39.3) 24 (40.0) 46 (39.7)
KRAS WT 34 (60.7) 36 (60.0) 70 (60.3)
Figure 1. Study consort diagram.
Total patients 
randomized to study
(n = 238)
Total number of patients
with plasma samples 
available (n = 159)
Total patients for analysis 
(n = 152)
Excluded for lack of consent (n = 3) 
Insufficient sample (n = 2) 
Ineligible (n = 2)
KRAS status tested (codons 12 and 13)
No Data (n = 36)
KRAS WT (n = 70; 60.3%)
KRAS Mutant (n = 46; 39.7%)
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Figure 2. Prognostic forest plots showing the association of each marker with PFS (A, C, and E) or OS (B, D, and F) for all patients (A and B), KRAS 
WT patients (C and D), and KRAS Mut patients (E and F).
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CI = 0.96–2.69, P = 0.072). No prognostic associations 
were observed between HBEGF and PFS (P = 0.42) or 
OS (P = 0.63) in the KRAS Mut group.
EGFR is the direct molecular target of cetuximab and 
tumor levels of EGFR protein have been studied exten-
sively as a potential predictive biomarker of cetuximab 
efficacy [29–32]. In the overall population of this study, 
and in the KRAS WT group, plasma levels of EGFR were 
not prognostic for PFS or OS. However, in KRAS Mut 
patients, higher EGFR levels were prognostic for both 
longer PFS (HR = 0.44, 95% CI = 0.26–0.74, P = 0.002) 
and longer OS (HR = 0.43, 95% CI = 0.23–0.80, 
P = 0.009).
In the overall population and in the KRAS WT group 
there were no prognostic associations observed between 
HER2 and PFS or OS. In KRAS Mut patients, higher 
HER2 was prognostic for longer PFS (HR = 0.40, 95% 
CI = 0.17–0.92, P = 0.031), but not OS (P = 0.52).
In the overall population, there was no prognostic 
association observed between levels of HER3 and PFS 
(P = 0.29). In the overall population, higher HER3 levels 
were prognostic for shorter OS (HR = 2.17, 95% CI = 1.03–
4.58, P = 0.042). In the KRAS WT and KRAS Mut groups, 
there was no prognostic association observed between 
HER3 and PFS or OS.
CD73 has been implicated as a potential predictive 
biomarker for cetuximab in several reports, including 
our previous analysis of mRNA expression in FFPE 
samples from CALGB 80203 [17, 18]. In the current 
analysis, in the overall population higher plasma CD73 
was prognostic for shorter OS (HR = 1.26, 95% 
CI = 1.04–1.52, P = 0.018). No additional prognostic 
associations between CD73 with PFS or OS were observed 
in the overall population or in the KRAS groups. All 
prognostic analyses for each marker are presented in 
Table S3.
Predictive­marker­analyses
In the overall population, EGF protein levels were not 
predictive of PFS (interaction P = 0.233) or OS (interac-
tion P = 0.748) benefit from cetuximab, but EGF levels 
were predictive within the individual KRAS groups. In 
the KRAS WT group, low EGF levels were predictive of 
OS benefit from cetuximab (chemo HR = 0.98, 95% 
CI = 0.74–1.29; chemo+cetuximab HR = 1.54, 95% 
CI = 1.05–2.25; interaction P = 0.045) (Fig. 3, panel A). 
In the KRAS Mut group, high EGF was predictive of 
benefit from cetuximab in both PFS (chemo HR = 2.16, 
95% CI = 1.29–3.63; chemo+cetuximab HR = 0.76, 95% 
CI = 0.56–1.03; interaction P = 0.001) and OS (chemo 
HR = 1.72, 95% CI = 1.02–2.92; chemo+cetuximab 
HR = 0.90, 95% CI = 0.67–1.21; interaction P = 0.026) 
(Fig. 3, panels B and C).
Levels of HBEGF, EGFR, and HER2 were not predictive 
for either PFS or OS in the overall population or in 
either of the KRAS subgroups.
In the overall population, levels of HER3 were predic-
tive for both PFS (chemo HR = 3.90, 95% CI = 1.41–10.80; 
chemo+cetuximab HR = 0.66, 95% CI = 0.25–1.78; inter-
action P = 0.032) and OS (chemo HR = 4.82, 95% 
CI = 1.68–13.84; chemo+cetuximab HR = 0.95, 95% 
CI = 0.31–2.95; interaction P = 0.046) (Fig. 4, panels A 
and B). It should be noted that the predictive role of 
HER3 was sensitive to the presence of an outlier with 
an extremely high level of plasma HER3. When this patient 
was removed from the analysis, HER3 was no longer 
predictive at P = 0.05, but the trends remained (PFS 
interaction P = 0.098, OS interaction P = 0.128). 
Interestingly, this patient did not have extreme values for 
any of the other markers examined, indicating that the 
high HER3 levels were unlikely due to preanalytic issues, 
such as sample handling, and may reflect the true levels 
of HER3 within this patient.
In the overall population, CD73 levels were predictive 
of PFS benefit across all patients (chemo HR = 1.38, 95% 
CI = 1.08–1.77; chemo+cetuximab HR = 0.84, 95% 
CI = 0.63–1.12; interaction P = 0.018) (Fig. 5, panel A), 
but there was no predictive association observed between 
CD73 protein levels and OS. In the KRAS WT group, 
CD73 levels were predictive of PFS benefit from cetuximab 
(chemo HR = 1.32, 95% CI = 0.92–1.90; chemo+cetuximab 
HR = 0.61, 95% CI = 0.36–1.04; interaction P = 0.017) 
(Fig. 5, panel B) and OS benefit from cetuximab (chemo 
HR = 1.28, 95% CI = 0.88–1.84; chemo+cetuximab 
HR = 0.60, 95% CI = 0.32–1.13; interaction P = 0.049) 
(Fig. 5, panel C). No predictive effects for CD73 were 
observed in KRAS Mut patients.
Comparison­of­plasma­proteins­and­tumor­
mRNA­expression
We previously identified several potential prognostic and 
predictive biomarkers from CALGB 80203 evaluating 
mRNA expression from FFPE tumor biopsies. In that 
work, we found that tumor expression of HER3 and 
CD73 were predictive biomarkers for cetuximab. The 
concordance between tumor- based gene expression and 
plasma- derived protein levels were explored. There were 
71 patients who had both FFPE and plasma sample avail-
able for this concordance analysis. Across most samples, 
there was little association between tumor mRNA expres-
sion and plasma protein levels. EGF, HBEGF, EGFR, 
HER2, and CD73 exhibited no correlation between plasma 
2255© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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protein levels and tumor mRNA expression levels. 
However, plasma HER3 protein and tumor HER3 mRNA 
expression were modestly correlated with one another 
(τ = 0.22, P = 0.010).
Figure 3. Kaplan–Meier curves showing the effects of EGF level and 
treatment arm. (A) OS KRAS WT patients (interaction P = 0.045); (B) PFS 
in KRAS Mut patients (interaction P = 0.001); (C) OS in KRAS Mut 
patients (interaction P = 0.026). High and low marker levels are 
dichotomized at the median. OS, overall survival; PFS, progression- free 
survival; EGF, epidermal growth factor.
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Figure 4. Kaplan–Meier curves showing the effects of HER3 level and 
treatment arm. (A) PFS in all patients (interaction P = 0.032); (B) OS in all 
patients (interaction P = 0.046). High and low marker levels are 
dichotomized at the median. OS, overall survival; PFS, progression- free 
survival.
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Discussion
Mutations in KRAS, and more recently NRAS and BRAF, 
are the only biomarkers regularly used for guiding the 
use of cetuximab in CRC and additional biomarkers are 
desperately needed. CALGB 80203 was initiated to evaluate 
cextuximab with FOLFOX or FOLFIRI chemotherapy in 
the first- line setting, but was closed due to slow enroll-
ment and the approval of bevacizumab as first- line therapy 
for CRC. After closure of CALGB 80203, a new intergroup 
study was initiated to directly compare the efficacy of 
cetuximab versus bevacizumab in mCRC. In CALGB 80405 
patients were randomized to receive standard chemotherapy 
with either bevacizumab (which targets vascular endothelial 
growth factor) or cetuximab in the first- line setting. As 
reported at ASCO in 2014, CALGB 80405 did not identify 
any significant PFS or OS differences between the beva-
cizumab and cetuximab cohorts in RAS WT patients [33, 
34]. These results underscore the need to identify bio-
markers beyond RAS that can select for patients who are 
most likely to benefit from cetuximab, as well as other 
targeted agents.
To identify biomarkers for cetuximab in mCRC, we 
assayed plasma levels of six proteins in patients that were 
either directly associated with the EGFR signaling pathway 
or previously implicated as potential biomarkers for cetuxi-
mab. Many of the evaluated proteins have been previously 
suggested as potential prognostic biomarkers; however, 
very few studies have evaluated the soluble levels of these 
proteins in patient plasma. While it is established that 
EGFR tumor levels are prognostic using immunohisto-
chemical approaches [35, 36], other readouts, including 
EGFR mRNA expression and copy number, are less con-
sistent [17, 37]. In the overall population, plasma EGF 
was prognostic for both OS and PFS, contradicting other 
observations from serum measurements of colon cancer 
patients [38]. However, differences could be due to the 
unknown KRAS status for patients in this earlier work 
or could reflect biological differences in plasma versus 
serum EGF levels. Interestingly, we observed that EGFR 
and HER2 were only prognostic in the KRAS Mut popu-
lation. However, for HER3, we observed that levels were 
prognostic for OS across all patients, but when analyzed 
based on KRAS mutational status, no associations were 
observed. In fact, no markers were prognostic within the 
KRAS WT group. While the impact of KRAS mutations 
on soluble HER receptors and ligand levels and their role 
Figure 5. Kaplan–Meier curves showing the effects of CD73 level and 
treatment arm. (A) PFS in all patients (interaction P = 0.018); (B) PFS in 
KRAS WT patients (interaction P = 0.017); (C) OS in KRAS WT patients 
(interaction P = 0.049). High and low marker levels are dichotomized at 
the median. OS, overall survival; PFS, progression- free survival.
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as prognostic factors remain unclear, no associations were 
observed between marker levels and KRAS mutation status 
in this study.
Protease- mediated shedding is important for the pro-
cessing of membrane- associated ligands and has been 
implicated in the regulation of EGFR levels [39–42]. Because 
soluble EGFR is competent to bind EGF [41], high levels 
of soluble receptors may act as ligand sinks that down-
regulate signaling through the EGFR pathway by reducing 
both the amount of free ligand and the amount of cell- 
surface receptors. Downregulation of HER3 protein on 
tumor cells is expected to improve outcomes from cetuxi-
mab therapy by reducing compensatory signaling through 
HER3- containing heterodimers. Increased HER3 protein 
in patient plasma could reflect a process of active shed-
ding as part of a homeostatic response to increased HER- 
axis signaling that may play a role in tumorigenesis. 
Strategies inhibiting hetero- dimerization between HER3 
and other HER family receptors have been promising 
[43–45], and targeting HER3 directly in a preclinical model 
has been effective in overcoming acquired resistance to 
cetuximab [46].
This study provides data consistent with a model in 
which HER3 mediating resistance to cetuximab. HER3 
shedding may suggest down-regulation of this resistance 
pathway. In this study, plasma protein levels of HER3, 
measured by ELISA, and HER3 mRNA from FFPE tumor 
tissue, measured using real- time PCR, were found to be 
modestly correlated with each other (τ = 0.22, P = 0.010). 
However, these comparisons should be considered highly 
exploratory because not only were different methods used, 
tumor protein was not analyzed, and all tumor mRNA 
samples were isolated from the surgical resection of the 
primary tumor, which often occurred years before the 
collection of plasma on this trial.
CD73 is an extracellular 5’ ectonucleotidase that func-
tions with CD39 (ecto- ATPase), adenosine kinase (AK; 
phosphorylation to form AMP), and adenosine deaminase 
(ADA; deamination to inosine) to convert proinflamma-
tory extracellular ATP to anti- inflammatory adenosine. 
The effects of extracellular adenosine on T- cell function 
and the emerging role of CD73 and purinergic signaling 
in cancer immunotherapy have been reviewed elsewhere 
[47–49]. Inhibition of CD73 enhances the effects of 
immune checkpoint inhibitors in a preclinical model fur-
ther supporting a role for CD73 in suppression of anti-
tumor immune responses [50]. CD73 is expressed on 
lymphocytes and endothelial cells and mature CD73 is 
linked to the extracellular surface by a glycosyl phos-
phatidyl inositol anchor. The mechanism by which CD73 
is released into the plasma remains to be studied, but 
higher levels of CD73 may reflect a mechanism of active 
shedding to regulate the immune- modulatory effects of 
CD73 on lymphocytes and other immune cell 
populations.
While intriguing, there are several limitations to the 
findings of this study. While CALGB 80203 was randomized, 
the number of available samples was limited and the cur-
rent biomarker analyses were developed retrospectively after 
completion of the study. The markers included in this 
study provide a cross section of factors related to EGFR/
HER- family signaling that includes both ligands and soluble 
receptors. Acknowledging the high number of factors capable 
of signaling through the EGFR/HER- family of receptors, 
additional studies are required to comprehensively inves-
tigate the levels of all potential ligands as potential predic-
tive biomarkers for EGFR- targeting therapies in CRC. Lastly, 
there are several characteristics of CALGB 80203 that make 
this study unique, most interesting being that KRAS muta-
tion status was not independently predictive of benefit from 
cetuximab. Additionally, the P- values reported here have 
not been adjusted for multiple testing so conclusions must 
be considered preliminary and hypothesis generating.
In conclusion, we have identified several potential blood- 
based, predictive, protein biomarkers of benefit from 
cetuximab in mCRC. Though these results should be 
considered preliminary, and further validation is required 
before any clinical application of these results, they provide 
further evidence supporting HER3- targeting therapeutic 
strategies and implicate immune modulation as an impor-
tant factor in the response to cetuximab. These results 
deserve further study and analyses of these markers in 
CALGB 80405 are currently ongoing.
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